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Background/aim: The purpose of the present study was to explore the neuroprotective role of delta opioid receptors (DOR) in the rat
cortex in hypoxic preconditioning.
Materials and methods: Rats were randomly divided into 8 groups: control (C), sham (S), hypoxic preconditioning (PC), severe hypoxia
(SH), PC + SH, PC + SH + Saline (PS), PC + SH + DPDPE (DPDPE, selective DOR agonist), PC + SH + NT (NT, Naltrindole, selective
DOR antagonist). Drugs were administered intracerebroventrically. Twenty four h after the end of 3 consecutive days of PC (10% O2,
2 h/day), the rats were subjected to severe hypoxia (7% O2 for 3 h). Bcl-2 and cyt-c were measured by western blot, and caspase-3 was
observed immunohistochemically.
Results: Bcl-2 expressions in the PC group were higher than in control, SH, and PC + SH groups. Even though there were no significant
differences between the groups in terms of cyt-c levels, caspase-3 immunoreactivity of cortical neurons and glial cells in the severe
hypoxia and NT groups were higher than in the control, sham, and hypoxic preconditioning groups. DPDPE administration diminished
caspase-3 immunoreactivity compared with all of the severe hypoxia groups.
Conclusions: These results suggest that cortical cells are resistant to apoptosis via increased expression of Bcl-2 and decreased
immunoreactivity of caspase-3 in the cortex, and that DOR is involved in neuroprotection induced by hypoxic preconditioning via the
caspase-3 pathway in cortical neurons.
Key words: Hypoxic preconditioning, delta opioid receptors, neuroprotection

1. Introduction
Hypoxia can occur due to natural causes, such as travel
to or living in high altitudes, or it can occur because of
pathological events such as ischemia, cardiac arrest, or
blood loss. Neurons of the central nervous system are
particularly sensitive to different forms of hypoxia because
of their high metabolic demands and limited glucose
storage capacity. Hypoxia/ischemia triggers a variety
of processes that lead to changes in intracellular signal
transduction, membrane function, metabolism, and even
cell morphology [1,2]. These processes may cause cellular
damage or death.
Hypoxic or ischemic preconditioning (PC or IPC)
is based on a phenomenon in which transient and mild
hypoxia/ischemia set cells and increase cellular resistance
against subsequent lethal ischemic/hypoxic injury. In
recent years, several studies have shown the protective
effects of PC/IPC on different organs such as the kidney,
lung, and heart in both in vivo and in vitro experimental

settings [3–7]. However, information on the underlying
mechanisms of PC/IPC which provide protection against
ischemic/hypoxic insults is limited, and still being
investigated.
Endogenous
opioid
peptides
function
as
neurotransmitters or neuromodulators in the central
nervous system and exert their effects via mu, delta, and
kappa receptors (MOR, DOR, and KOR, respectively).
These receptors are G protein-coupled receptors (GPCR)
and are common in the central nervous system [8].
Several studies have shown that among all opioid
receptors, DOR is the most sensitive to stressors like
hypoxia/ischemia, and it may have a role in neuroprotective
processes against hypoxic/ischemic stress [9].
DOR has been shown to be more abundant in the turtle
brain than in the rat brain; concordant with this, neurons in
turtle brain are much more resistant to hypoxic/ischemic
stress [10,11]. DOR expression in the rat brain cortex is
more prominent compared to subcortical areas such as the
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thalamus, hippocampus, or brain stem [12]; in addition,
the cortex is more tolerant to hypoxic stress [13–15]. DOR
expression is heterogeneous in cortex tissue. Outer and
inner layers of the cortex have a higher density than the
middle layer and are more resistant to hypoxia/ischemia
than the middle layer [15–17]. Moreover, it has been shown
that a DOR ligand, enkephalin, increases during hypoxia
[18–20]. Several ischemia or stroke models performed on
rats have shown that DOR upregulation or administration
of central and peripheral DOR agonists decreased infarct
volume, neurological deficits, and neuronal loss, and
increased neuronal survival particularly in the cortex and
hippocampus after ischemia [21–25]. DOR signals have
been shown to protect ionic homeostasis at the beginning
of hypoxia [1,26,27] and to increase the expressions and
functions of beneficial signal molecules, and to decrease
the expression and function of molecules which are related
with cellular injury and death during long-term hypoxia
[9,28,29].
All of these findings suggest that DOR expression
may have an important role in neuroprotective processes
during hypoxic/ischemic conditions. However, most of the
studies on the protective effect of DOR against hypoxic/
ischemic injury via preconditioning are in vitro studies,
and information about in vivo systems is limited.
Therefore, hypoxic/ischemic preconditioning-related
neuroprotective effects of DOR on hypoxic/ischemic
processes still need to be clarified. With the present study,
we aimed to investigate in vivo the neuroprotective role
of delta opioid receptors [DOR] in the rat cortex in the
presence of hypoxic preconditioning.
2. Materials and methods
Animal experiments were performed in accordance with
the guidelines issued by the Ethical Committee of Gazi
University Faculty of Medicine.
The Wistar albino rats were maintained under
standard animal care conditions (12:12 h light–dark cycle,
room temperature 21 °C, with standard rat chow and tap
water ad libitum). Experimental groups were as follows:
1. control (C); 2. sham (S); 3. hypoxic preconditioning
(PC); 4. severe hypoxia (SH); 5. hypoxic preconditioning
+ severe hypoxia (PC + SH); 6. hypoxic preconditioning
+ severe hypoxia + physiological saline (PS); 7. hypoxic
preconditioning + severe hypoxia + DPDPE (DPDPE, a
delta opioid receptor agonist); 8. PC + SH + Naltrindol (NT,
a delta opioid receptor antagonist). Number (n) of subjects
in the groups were between 4 and 6 each, explained in the
relevant figures in the results section.
All rats except for those in the control group were
anesthetized with ketamine (90 mg/kg) and xylazine (5
mg/kg) and then placed in a stereotaxic instrument. A
22-gauge stainless steel guide cannula was inserted into

the lateral cerebral ventricle (AP: 0.8 mm, L: 1.5 mm).
Animals were allowed to recover for at least 1 week before
experiments.
Severe hypoxia (SH) was produced by using 7%
normobaric oxygen for 3 h in a normobaric chamber. For
hypoxic preconditioning, the animals were kept at 10%
normobaric oxygen for 2 h daily for 3 days before SH.
Before the SH bout, 25 μg DPDPE, NT, or PS was applied
to the rats intracerebroventricularly.
After hypoxia protocols, the rats were anesthetized
with ketamine (90 mg/kg) and xylazine (5 mg/kg) cocktail
and decapitated. Their cortices were rapidly removed, and
frozen immediately in liquid nitrogen, and stored at –80
°C.
2.1. Western blot analysis
Each sample was homogenized in RIPA buffer (10 μL/
mg) containing a 10 μL/mL protease inhibitor cocktail
(Halt Protease Inhibitor Single-Use Cocktail, Thermo
Scientific) on ice. Lysates were centrifuged at 15,000 × g
for 15 min at 4 °C and supernatants were removed; protein
concentrations were then determined by using a BCA
protein assay kit (Novagen, BCA Protein Assay Kit, Merck
Millipore, Darmstadt, Germany). Supernatants were then
boiled in the sample buffer for 5 min. Then, 20 μg (for
Bcl-2) and 60 μg (for cyt-c) protein samples were loaded
onto 15% sodium dodecyl sulfate–polyacrylamide gels,
separated electrophoretically, and transferred to PVDF
membranes (Millipore Corporation, Billerica, MA, USA).
The membranes were incubated in blocking buffer (5%
milk in Tris-buffered saline [TBS] with 0.1% Tween 20)
for 1 h at room temperature, followed by a 1.5 h incubation
for Bcl-2 and beta actin, and by an overnight incubation
for cyt-c at 4 °C with primary antibodies (Cell Signaling
Technology, Bcl-2, #2870, 1:3000; cyt-c #4280, 1:1000; beta
actin, Thermo Scientific PA1-46296, 1:2000) Beta actin
was used as the loading control. After washing 3 times in
TBS containing 0.1% Tween-20, the appropriate secondary
antibody (HRP- conjugated IgG) was applied at a 1:5000
dilution for 1.5 h (Cell Signaling Technology, #7074). The
membranes were then washed 3 times in TBS. Blots were
developed by using Luminata Crescendo Western HRP
Substrate (Millipore) and were exposed on the X-ray films.
Signals were quantified by gel densitometry scanning in
Image J software (Wayne Rasband, National Institutes
of Health, Bethesda, MD, USA). Each experiment was
repeated 3 times to determine the average value.
2.2. Immunohistochemistry for caspase-3
Cortex tissues from each group were fixed in 10% neutral
formalin for 72 h and processed for paraffin embedding.
For immunohistochemical demonstration, sections of
4–5 μm thickness was mounted on polylysine-covered
microscope slides. The slides were incubated in a
microwave oven in 0.01 M/L citrate buffer (pH: 6.0, Cat:
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AP-9003-500, Lot: 9003LT13610, LabVision, Fremont,
CA, USA). Endogenous peroxidase activity was blocked
in 3% hydrogen peroxide (Cat: TA-125-HP, Lot: HP23491,
Thermo, Fremont, CA, USA). Epitopes were stabilized
by application of serum blocking solution (Ultra V Block
Cat: TA-125-HL, Lot: RHL-120705, Thermo); slides were
then incubated with anticaspase-3 primary antibody
(RB-1197-P, Lot: 11010N, Thermo) for 45 min at room
temperature. The biotinylated secondary antibody (Cat:
TA-125-HL, Lot: RHL-120705, Thermo) streptavidin–
peroxidase (Cat: TA-125-HL, Lot: RHL-120705, Thermo)
was applied to the slides. 3-Amino-9-ethylcarbazole
(Cat: TA-125-SA, Lot: ASA130503, Thermo) was used as
a chromogen. Counterstaining was done using Mayer’s
hematoxylin (Cat: TA-125-MH, Lot: AMH70809,
LabVision, Fremont, CA, USA). Sections were evaluated
in the Leica Q Vin 3 program by obtaining images with a
Leica DM 4000 (Wetzlar, Germany) computer-supported
imaging system.
The distribution and intensity patterns of caspase-3
immunohistochemical
staining
were
evaluated
using H-score. Serial sections were examined and
2.0

immunolabeling patterns were compared. The labeling
intensities were graded semiquantitatively and the H-score
was calculated by using the following equation: H-SCORE
= ∑Pi (i + 1), where i = intensity of labeling with a value of
1, 2, or 3 (weak, moderate, or strong, respectively), and Pi
is the percentage of labeled cells for each intensity, varying
from 0% to 100% [30].
2.3. Statistical analysis
Data are represented as mean ± S.E.M. Statistical analysis
was performed with the one-way analysis of variance
(ANOVA) with Fisher’s LSD post hoc test. A difference
with P < 0.05 was considered statistically significant.
3. Results
3.1. Western blotting
The differences in the mean values among groups for
the Bcl-2 levels were significant (ANOVA F: 4.810, P <
0.001). Bcl-2 expressions in the hypoxic preconditioning
group were significantly higher than in the control (P <
0.05), severe hypoxia (P < 0.05), and PC + SH groups (P <
0.05) (Figure 1). Cyt-c expressions were not significantly

*
*

*

#

1.5

‡

Bcl 2/beta actin

‡

1.0

0.5

0.0
C

S

PC

SH

PC+SH

PS

NT

DPDPE

Figure 1. Bcl-2 (26 kD) expressions (n = 6). 20 µg protein was loaded in each well.
Beta actin (46 kD) was used as loading control. * C vs PC: P < 0.05, Bcl-2 levels were
increased in PC group. ‡ PC vs PC + SH, P < 0.001; Bcl-2 levels were decreased in
the PC + SH group. # PC vs SH, P < 0.05; Bcl-2 levels were decreased in the severe
hypoxia group.
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different among the groups (ANOVA F: 0.662, P > 0.05)
(Figure 2). DPDPE and NT had no significant effect on the
Bcl-2 and cyt-c expressions (Figures 1 and 2).
3.2. Immunohistochemistry
The differences in the mean values of H-scores amongst
the groups are significant (ANOVA F: 673.035, P < 0.001).
Cortical neurons and glial cells had normal histological
structures in the control group (Figure 3). Caspase-3
immunoreactivity of these cells was also quite low. In
the sham group (Figure 3), there were some neurons
distinguished with degenerated nuclei; these neurons
showed higher caspase-3 immunoreactivity than the
control group. However, when all of the tissue samples
were analyzed, there were no significant differences
between the control and sham groups in terms of caspase-3
immunoreactivity. Caspase-3 immunoreactivity of cortical
neurons and glial cells in the severe hypoxia (Figure 4) and
NT (Figure 5) groups was higher than in the control and the

hypoxic preconditioning groups (Figure 3) (P < 0.001). As
in the PC + SH group (Figure 4), in the PS group, caspase
3 immunoreactivity of cortical neurons and glial cells was
lower than in the NT group (P < 0.001) (Figure 4).
There was no significant difference between the
severe hypoxia and NT groups. Strong caspase-3
immunoreactivity was seen in both groups. The caspase-3
immunoreactivity of neurons and glial cells in the PC + SH
and DPDPE groups (Figure 5) was lower than in the severe
hypoxia and NT groups (P < 0.001), but not lower than in
the control (Figure 3), hypoxic preconditioning, and sham
groups. Caspase-3 immunoreactivity in the DPDPE group
was lower than in the PC + SH group (P < 0.001) (Figure 6).
4. Discussion
Our results in this study showed that in the presence of
hypoxic preconditioning, DOR agonist DPDPE may protect
cortical neurons by reducing caspase-3 immunoreactivity
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Figure 2. Demonstration of Cyt-c (14 kD) expressions; 60 µg protein was loaded in
each well. Beta actin was used as loading control (46 kD). (n numbers for C: 4, S: 6,
PC: 5, SH: 6, PC + SH: 6, PS: 3, NT and DPDPE: 4).
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Figure 3. In the control group, neurons are seen in their normal histological structures. While caspase-3 immunoreactivity is
significantly weak in some neurons, immunoreactivity in glial cells has not been determined (1). In the sham group, caspase-3
immunoreactivity appears to be weak in neurons (2A). In some areas, neurons with degenerated nucleus were distinguished (2B).
When compared to the sham group, caspase-3 immunoreactivity was increased in the hypoxic preconditioning group. Involvement
changed from weak to moderate. In this group, positive immunoreactive glial cells were also relatively increased (3). (→): positive
caspase-3 immunoreactive cells, (Æ): negative caspase 3 immunoreactive cells (immune peroxidase–hematoxylin ×400; n = 6 for each
group).

Figure 4. Involvement of caspase-3 immunostaining in the severe hypoxia group was significantly strong in some neurons. In contrast
to the other groups, caspase-3 immunoreactivity was also seen in glial cells (1). In the PC + SH group, the involvement of caspase-3
immunoreactivity decreased when compared to the severe hypoxia group. Immunoreactive cells were shown at different cortical
regions in 2A and 2B. Involvement of caspase-3 immunostaining of PS group was found to be similar to that of the PC + SH group in
both neurons and glial cells (3). (→): positive caspase-3 immunoreactive cells, (Æ): negative caspase 3 immunoreactive cells (immune
peroxidase–hematoxylin ×400; n = 6 for each group).

triggered by severe hypoxia. Since the frontal cortex is
one of the most vulnerable areas in the brain [31,32], we
investigated the effect of delta opioid receptors on hypoxic
preconditioning-mediated neuroprotection in the frontal
cortex.
Hypoxic preconditioning is known to have a protective
effect on vital organs such as the heart and brain. Short-term
protective effects of preconditioning (minutes to hours)
include activation and posttranslational modification of
existing proteins. However, long-term effects (hours to
days) of it are related to the synthesis of new proteins. In
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several hypoxic preconditioning models, DOR receptors
have been shown to have protective effects on heart and
brain tissues in particular. These protective effects of DORs
are related with ionic homeostasis, neuronal conductance,
neurotransmitter release, and regulation of apoptotic and
proapoptotic signal pathways. The DORs-G protein-PKCpERK-Bcl-2 pathway is the most important pathway in
opiodergic neuroprotection; in several studies, hypoxic
preconditioning has been shown to activate this pathway
[9,28,33,34]. In our study, the antiapoptotic protein Bcl-2
levels increased with hypoxic preconditioning; this finding

GÜNEY et al. / Turk J Med Sci

Figure 5. When compared to the severe hypoxia group, caspase-3 involvement was decreased in the DPDPE group. However, in this
group, some glia cells showed caspase-3 immunoreactivity as in the severe hypoxia group (1). Caspase-3 involvement in the NT group
was increased compared to that of the DPDPE group, and caspase-3 immunoreactivity was found to be similar to that of the severe
hypoxia group. Unlike the severe hypoxia group, condensations in the nucleus and cytoplasm were noticed in some neurons (2). (→):
positive caspase-3 immunoreactive cells, (Æ): negative caspase 3 immunoreactive cells (immune peroxidase–hematoxylin ×400; n =
6 for each group).
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Figure 6. H scores of caspase-3 immunoreactivity. ¶ Immunoreactivity of PC group
was higher than in the C and S groups. *Compared with the C, S, and PC groups,
immunoreactivity was higher in the SH, PC + SH, PS, NT groups (P < 0.001). ‡ The PC +
SH and DPDPE groups have lower caspase-3 immunoreactivity than SH and NT groups (P
< 0.001). # Levels of caspase-3 immunoreactivity were lower in the DPDPE group than in
the PC + SH group (P < 0.001).

is consistent with studies showing increased Bcl-2 levels
through hypoxic preconditioning [35–39].
However, the increase in Bcl-2 levels was not observed
in the groups that were treated with both preconditioning
and severe hypoxia together. Treatments of DOR agonist or
antagonist also did not show statistically significant effects
of Bcl-2 and cyt-c levels in these groups. In severe hypoxia

and anoxia conditions, cells activate a series of pathways
leading to apoptosis. The initiation of apoptosis depends
on the ratio between activator and inhibitor molecules.
Therefore, the Bax/Bcl-2 ratio is an important determinant
for initiating apoptosis [40]. Rybnikova et al. [41] showed
that severe hypoxia did not affect the Bcl-2 levels in the
hippocampus and neocortex, while proapoptotic protein
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Bax levels were increased by severe hypoxia. Therefore, they
suggested that increased Bax/Bcl-2–Bcl-xL ratio triggered
neuronal apoptosis. In the present study, we did not
measure Bax levels or the Bax/Bcl-2 ratio; this is one of the
limitations of our study. The first 2–4 hours after hypoxic/
ischemic injury are important for cyt-c release from
mitochondria and ensuing apoptotic cascades [41,42]. In
our study, tissue samples were collected immediately after
severe hypoxia administration; this could be the reason for
no significant changes in cyt-c levels. Hypoxic/ischemic
preconditioning increases the synthesis of antiapoptotic
proteins like Bcl-2 and Bcl-xL, while it decreases synthesis
of caspase-3, and causes a decrease in p53 activation and
cyt-c release from mitochondria [43]. Ma et al. [9] have
suggested that neuroprotective effects of DORs in hypoxic
preconditioning involve the DOR-G protein-PKC-pERKBcl-2 signaling pathway; stimulation of this pathway by
preconditioning increases levels of protective proteins
such as Bcl-2 and inhibits death signals like p38 MAPKmediated cyt-c release from mitochondria.
Peng et al. [28] showed that hypoxic preconditioning
is neuroprotective against intraocular pressure-induced
stress in rat retinas. The protective mechanism here is
related to the restoration of redox imbalance and the
inhibition of proapoptotic caspase-3 via stimulation of
the DOR-ERK pathway. In the present study, caspase-3
immunoreactivity increased significantly in response
to severe hypoxia, and this increase was extenuated by

hypoxic preconditioning treatment. Moreover, DPDPE
treatment after hypoxic preconditioning and before severe
hypoxia reduced this increase a bit more. DOR antagonist
Naltrindole diminished the effectiveness of hypoxic
preconditioning in extenuating the increase of caspase-3
immunoreactivity. This finding is compatible with those of
the studies which show that DORs are protective against
hypoxia/ischemia-induced apoptotic processes. There
have also been some studies which underline the important
role of DORs in ionic homeostasis during hypoxic/
ischemic conditions [44]. Cellular ionic homeostasis has
a well-known substantial effect on the activation of the
mitochondria-related intrinsic pathway of apoptosis. In
the present study, we did not investigate this pathway.
In conclusion, our results suggest that cortical cells
are resistant to apoptosis via increased expression of Bcl-2
and lowered immunoreactivity of caspase-3 in the cortex,
and that DOR is involved in neuroprotection induced
by hypoxic preconditioning via caspase-3 pathway in
cortical neurons. However, our findings are not sufficient
to explain the mechanism of DOR-mediated protection
against hypoxic/ischemic insult.
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